Clinical trial of 3,4-diaminopyridine(3,4-DAP) for the Lambert-Eaton myasthenic syndrome

Clinical trial of 3,4-diaminopyridine(3,4-DAP) for the Lambert-Eaton myasthenic syndrome - Clinical trial of 3,4-diaminopyridine(3,4-DAP) for the Lambert-Eaton myasthenic syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029085

Enrollment

Registered

2017-10-01

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lambert-Eaton myasthenic syndrome(LEMS)

Interventions

3,4-DAP Period from consent this trial to correspond the stop criteria Dose 15-80mg/day number of dose three times a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients who receive a diagnosis of the Lambert-Eaton myasthnic syndrome 2. In the patients who administer anti-cholinesterase drug, there are no obvious improvement of clinical manifestation and EMG findings within 2 weeks. 3. The patients that an agreement is provided in this clinical trial.

Exclusion criteria

Exclusion criteria: 1. serum anti-acetylcholie receptor antibody positive 2. serum anti-MuSK antibody positive 3. pregnancy 4. epilepsy 5. iver dysfunction 6. renal dysfunction 7. abnormal ECG findings 8. the patient who judged inappropriate from the doctor

Design outcomes

Primary

Measure	Time frame
Improvement of Manual Muscle Testing(MMT) and Hand grasping power	—

Secondary

Measure	Time frame
Improvement of repetitive stimulation test findings	—

Countries

Japan

Contacts

Public ContactKazuaki Nagashima

Gunma university hospital neurology

nagakazu@gunma-u.ac.jp027-220-8538

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026